TABLE 1

Proportion of subjects with hSBA titers of ≥8 in the intention-to-treat population

Primary vaccineSecondary vaccineNo. of subjects with titers of ≥8/total no. of subjects; % (95% CI)
28 days after primary10 mo after primary28 days after 2nd vaccined14 mo after 2nd vaccined
PsA-TT42/57; 73.7a (60.3, 84.5)11/55; 20.0b (10.4, 33.0)
PsA-TT11/13; 84.6 (54.6, 98.1)12/15; 80.0 (51.9, 95.7)
PsACWY22/22; 100.0 (84.6, 100.0)16/22; 72.7 (49.8, 89.3)
Hib3/18; 16.7 (3.6, 41.4)4/19; 21.1 (6.1, 45.6)
PsACWY20/61; 32.8c (21.3, 46.0)1/61; 1.6 (0.0, 8.8)
PsA-TT13/19; 68.4 (43.4, 87.4)7/20; 35.0 (15.4, 59.2)
PsACWY9/17; 52.9 (27.8, 77.0)5/18; 27.8 (9.7, 53.5)
Hib2/21; 9.5 (1.2, 30.4)8/22; 36.4 (17.2, 59.3)
Hib8/62; 13.1 (5.8, 24.2)3/59; 5.1 (1.1, 14.1)
PsA-TT6/16; 37.5 (15.2, 64.6)5/16; 31.3 (11.0, 58.7)
PsACWY4/22; 18.2 (5.2, 40.3)3/20; 15.0 (3.2, 37.9)
Hib1/18; 5.6 (0.1, 27.3)4/19; 26.3 (9.1, 51.2)
  • a Fisher's exact test of percentage of subjects with titers of ≥8, P < 0.0001 for PsA-TT compared to PsACWY and compared to Hib at 28 days after primary immunization.

  • b Fisher's exact test of percentage of subjects with titers of ≥8, P = 0.0014 for PsA-TT compared to PsACWY, and P = 0.0212 for PsA-TT compared to Hib at 10 months after primary immunization.

  • c Fisher's exact test of percentage of subjects with titers of ≥8, P = 0.0169 for PsACWY compared to Hib at 28 days after primary immunization.

  • d No significance testing performed.